earnings
confidence high
sentiment positive
materiality 0.65
LENSAR Q1 2022 revenue $9.3M (+33% YoY); net loss $6.7M; ALLY 510(k) under FDA review
LENSAR, Inc.
2023-Q1 EPS reported
-$0.67
revenue$9,340,000
- Total revenue $9.3M, up 33% from $7.0M in Q1 2021; 89% from recurring sources.
- Procedure volume 38,901, up 38% YoY; product, lease, and service revenue all increased.
- Net loss $6.7M ($0.67 per share) vs $5.2M ($0.56) in Q1 2021; R&D expense rose 74% to $4.8M due to ALLY development.
- FDA accepted 510(k) for ALLY Adaptive Cataract Treatment System; launch anticipated in 2022 if cleared.
- Adjusted EBITDA was ($4.2)M vs ($2.2)M in Q1 2021; stock-based comp $1.6M.